Associate Research Scientist (Tenure Track)

Center for Human Genetics, MLR
Marshfield Clinic
1000 North Oak Avenue
Marshfield, WI 54449




One of Dr. Hebbring’s main interests is to identify genetic variants associated with clinical phenotypes using phenome-wide association studies. He completed his Bachelor’s degree at the University of Wisconsin – Eau Claire and his doctoral degree in Biochemistry and Molecular Biology at the Mayo Clinic Graduate School. At the Mayo Clinic, Dr. Hebbring’s research included the study of genes and enzymes involved in folate metabolism, pharmacogenomics, and prostate cancer.



  • My research interests include understanding how genetics contributes to human health. There are many examples of genetic variants/mutations that cause rare Mendelian diseases. Some of the best clinically relevant variants are loss of function mutations that result in a gene’s function being attenuated. Obvious examples could include nonsense, splicing, and frame-shift variants. Recent data from the “1000 Genomes Project” estimated that healthy individuals may carry between 50 and 100 known deleterious mutations causing inherited disorders. In addition, this study estimated that individuals may carry more than 250 novel loss-of-function variants, with many in clinically relevant genes. Given the importance of these types of variants as it relates to gene function and their potential role in human disease, my work is aimed at investigating the potential correlational role of loss of function polymorphisms, of unknown clinical relevance, with a spectrum of human disease phenotypes as defined by electronic health records within Marshfield Clinic’s Personalized Medicine Research Project.


Stephen Thibodeau, Ph.D. – Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota
Richard Weinshilboum, M.D. – Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota
Daniel Schaid, Ph.D. – Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota
Deborah Levy, Ph.D. – Psychology Research Laboratory, Psychotic Disorders Division, McLean Hospital, Belmont, Massachusetts


Hebbring SJ, Schrodi SJ, Ye Z, Zhou Z, Page D, Brilliant MH. A PheWAS approach in studying HLA-DRB1*1501. GENES IMMUN 2013 Feb.
PubMed ID: 23392276

Hebbring SJ, Slager SL, Epperla N, Mazza JJ, Ye Z, Zhou Z, Achenbach SJ, Vasco DA, Call TG, Rabe KG, Kay NE, Caporaso NE, Lanasa MC, Camp NJ, Strom SS, Goldin LR, Cerhan JR, Brilliant MH, Schrodi SJ. Genetic evidence of PTPN22 effects on chronic lymphocytic leukemia. BLOOD 2013;121:237-8.
PubMed ID: 23287625

Ji Y, Nordgren KK, Chai Y, Hebbring SJ, Jenkins GD, Abo RP, Peng Y, Pelleymounter LL, Moon I, Eckloff BW, Chai X, Zhang J, Fridley BL, Yee VC, Wieben ED, Weinshilboum RM. Human liver methionine cycle: MAT1A and GNMT gene resequencing, functional genomics, and hepatic genotype-phenotype correlation. DRUG METAB DISPOS 2012;40:1984-92.
PubMed ID: 22807109

Haas DM, Lehmann AS, Skaar T, Philips S, McCormick CL, Beagle K, Hebbring SJ, Dantzer J, Li L, Jung J. The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use. AM J OBSTET GYNECOL 2012;206:447:e17-24.
PubMed ID: 22445700

Abo R, Hebbring S, Ji Y, Zhu H, Zeng ZB, Batzler A, Jenkins GD, Biernacka J, Snyder K, Drews M, Fiehn O, Fridley B, Schaid D, Kamatani N, Nakamura Y, Kubo M, Mushiroda T, Kaddurah-Daouk R, Mrazek DA, Weinshilboum RM. Merging pharmacometabolomics with pharmacogenomics using ‘1000 Genomes’ single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. PHARMACOGENET GENOMICS 2012;22:247-53.
PubMed ID: 22322242

Hebbring SJ, Chai Y, Ji Y, Abo RP, Jenkins GD, Fridley B, Zhang J, Eckloff BW, Wieben ED, Weinshilboum RM. Serine hydroxymethyltransferase 1 and 2: gene sequence variation and functional genomic characterization. J NEUROCHEM 2012;120:881-90.
PubMed ID: 22220685